Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck

References

• Patel PR, Slama JK. Reirradiation for recurrent head and neck cancer. Expert Rev Anticancer Ther. 2012;12(12):1177–1189.
   PubMedGoogle Scholar
• Pai SI, Westra WH. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol. 2009;4(1):49–70.
   PubMedGoogle Scholar
• Solomon B, Young RJ, Rischin D. Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol. 2018;52(Pt 2):228–240.
   PubMedGoogle Scholar
• Fakhry C, Zhang Q, Nguyen-Tan PF, et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. Journal of Clinical Oncology. 2014;32(30):3365–3373. .
   PubMed Web of Science ®Google Scholar
• Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC. Head and neck cancer cooperative group. AnnOncol. 1994;5:521–526.
   Google Scholar
• Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer. 2004;101(10):2222–2229.
   PubMed Web of Science ®Google Scholar
• Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008;30(3):281–288. .
   PubMed Web of Science ®Google Scholar
• Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of radiation therapy oncology group protocol 9911. Journal of Clinical Oncology. 2007;25(30):4800–4805. .
   PubMed Web of Science ®Google Scholar
• Sulman EP, Schwartz DL, Le TT, et al. IMRT reirradiation of head and neck cancer—disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys. 2009;73(2):399–409. .
   PubMed Web of Science ®Google Scholar
• Salama JK, Vokes EE, Chmura SJ, et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2006;64(2):382–391. .
   PubMed Web of Science ®Google Scholar
• Vargo JA, Ward MC, Caudell JJ. et al. A Multi-institutional Comparison of SBRT and IMRT for definitive reirradiation of recurrent or second primary head and neck cancer. Int J Radiat Oncol Biol Phys. 2018;100(3):595–605.
   PubMed Web of Science ®Google Scholar
• Heron DE, Ferris RL, Karamouzis M, et al. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys. 2009;75(5):1493–1500. .
   PubMed Web of Science ®Google Scholar
• Vargo JA, Ferris RL, Ohr J, et al. A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck. International Journal of Radiation Oncology*Biology*Physics. 2015;91(3):480–488. .
   Web of Science ®Google Scholar
• Comet B, Kramar A, Faivre-Pierret M, et al. stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility. J RadiatOncolBiol Phys 2012;84(1):203–209. study.Int
   Google Scholar
• Vargo JA, Kubicek GJ, Ferris RL, et al. Adjuvant stereotactic body radiotherapy ± cetuximab following salvage surgery in previously irradiated head and neck cancer. The Laryngoscope. 2014;124(7):1579–1584. .
   PubMed Web of Science ®Google Scholar
• Lartigau EF, Tresch E, Thariat J, et al. Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer. RadiotherOncol. 2013;109(2):281–285.
   PubMedGoogle Scholar
• Heron DE, Rwigema J-CM, Gibson MK, et al. Concurrent Cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2011;34(2):165–172. .
   PubMed Web of Science ®Google Scholar
• KEYSTROKE:a randomized phase ii study of pembrolizumab (KEYTRUDA®) plus stereotactic re-irradiation versus SBRT alone for locoregionally recurrent or second primary head and neck carcinoma. Clinical Trials.gov: https://clinicaltrials.gov/ct2/show/NCT03546582
   Google Scholar
• Melero I, Berman DM, Aznar MA, et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015;15(8):457–472. .
   PubMed Web of Science ®Google Scholar
• Jie H-B, Srivastava RM, Argiris A, et al. Increased PD-1 + and TIM-3 + TILs during cetuximab therapy inversely correlate with response in head and neck cancer patients. Cancer Immunol Res. 2017;5(5):408–416. .
   PubMed Web of Science ®Google Scholar
• Taberna M, Oliva M, Mesía R. Cetuximab-containing combinations in locally advanced and recurrent or metastatic head and neck squamous cell carcinoma. Front Oncol. 2019;9:383.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health. 2013;16(2):e1–5. .
   PubMed Web of Science ®Google Scholar
• Murray CJL, Evans DB, Acharya A, et al. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Economics. 2000;9(3):235–251. .
   PubMed Web of Science ®Google Scholar
• International Monetary Fund. World economic outlook (April 2019) GDP current price. cited 2018 August 12. http://www.imf.org/external/datamapper/NGDPD@WEO/OEMDC/ADVEC/WEOWORLD
   Google Scholar
• Diaby V, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics. 2014;32(2):101–108.
   PubMed Web of Science ®Google Scholar
• Purmonen T, Martikainen JA, Soini EJO, et al. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland. Clin Ther. 2008;30(2):382–392. .
   PubMed Web of Science ®Google Scholar
• Kim H, Vargo JA, Beriwal S, et al. Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer. Head Neck. 2009;75(5):1743–1751. .
   Google Scholar
• Brown B, Diamantopoulos A, Bernier J, et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and Neck Cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health. 2008;11(5):791–799. .
   PubMed Web of Science ®Google Scholar
• Drummond MF, Mj S, Gw T. Methods for the economic evaluation of health care programs. Oxford, UK: Oxford University Press; 2005.
   Google Scholar
• Net benefits calculations, TreeAge Pro 2020 User’sManual. Chapter 33. TreeAge Software, Inc; 2020. p. 493.
   Google Scholar
• Gray A, Clarke PM, Wolstenholme JL, et al. Applied methods of cost-effectiveness analysis in health care. Oxford University Press; 2010.
   Google Scholar
• Sculpher Mark. The Use of a Probabilistic Sensitivity Analysis for Decision Making: the example of Drug Eluting Stents. 2008, Aug 17.
   Google Scholar
• Gray LA, Alava MH, Wailoo AJ. Development of methods for the mapping of utilities using mixture models: mapping the AQLQ-S to the EQ-5D-5L and the HUI3 in Patients with Asthma. Value Health. 2018;21(6):748–757.
   PubMed Web of Science ®Google Scholar
• Mihaylova B, Briggs A, O’Hagan A, et al. Review of statistical methods for analysing healthcare resources and costs. Health Economics. 2011;20(8):897–916.
   PubMed Web of Science ®Google Scholar
• The beta-PERT Distribution RiskAMP. https://www.riskamp.com/beta-pert. cited 2020 Dec 18.
   Google Scholar
• Shiroiwa T, Sung Y-K, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Economics. 2010;19(4):422–437. .
   PubMed Web of Science ®Google Scholar
• Vallejo-Torres L, García-Lorenzo B, Castilla I, et al. On the estimation of the cost-effectiveness Threshold: why, what, how? Value Health. 2016;19(5):558–566. .
   PubMed Web of Science ®Google Scholar
• Vallejo-Torres L, García-Lorenzo B, Castilla I, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ 2016;94(12):925–930.
   PubMed Web of Science ®Google Scholar
• Value assessment framework - proposed changes, page ES3. Institute for Clinical and Economic Review; 2019.
   Google Scholar
• Sun XS, Sire C, Tao Y, et al. A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): first results of the GORTEC 2015-01 “PembroRad” trial. J Clin Oncol. 2018;36(Suppl. 15_suppl):6018.
   Web of Science ®Google Scholar
• Levy A, Massard C, Soria J-C. Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: single centre subset analysis from a phase 1/2 trial. Eur J Cancer. 2016;68:156–162.
   PubMed Web of Science ®Google Scholar
• Powell SF, Gitau MM, Sumey CJ, et al. Safety of pembrolizumab with chemoradiation (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). J Clin Oncol. 2017;35(15_suppl):6011.
   Google Scholar
• Gillison M, Ferris R, Zhang Q, et al. Safety evaluations of nivolumab (anti-pd1) added to chemoradiotherapy platformsfor patientswith intermediate and high-risk local-regionally advanced headand neck squamous cell carcinoma. In: Multidisciplinary Head and Neck Cancers Symposium (Scottsdale, AZ). 2018.
   Google Scholar
• Wise-Draper TM, Old MO, Worden FP, et al. Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma. J Clin Oncol. 2018;36(suppl. 15_suppl):6017.
   Web of Science ®Google Scholar
• McBride SM, Sherman EJ, Tsai CJ, et al. A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2018;36(15_suppl):6009.
   Google Scholar
• Campo C, Bai J, Keller LR. Comparing Markov and non-Markov alternatives for cost-effectiveness analysis: insights from a cervical cancer case. Oper Res Health Care. 2019;21:32–43.
   Web of Science ®Google Scholar
• Wong SJ, MachtayM M, Li Y. Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? J Clin Oncol. 2006;24(17):2653–2658.
   PubMed Web of Science ®Google Scholar
• Tortochaux J, Tao Y, Tournay E, et al. Randomized phase III trial (GORTEC 98-03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent. Radiother Oncol. 2011;100(1):70–75.
   PubMed Web of Science ®Google Scholar
• Hannouf MB, Sehgal C, Cao JQ, et al. Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer. PLoS One. 2012;7(6):e38557.
   PubMed Web of Science ®Google Scholar
• Caudell JJ, Ward MC, Riaz N, et al. Volume, dose, and fractionation considerations for IMRT-based reirradiation in head and neck cancer: a multi-institution analysis. Int J Radiat Oncol Biol Phys. 2018;100(3):606–617.
   PubMed Web of Science ®Google Scholar